Titan Biotech Limited
BSE: TITANBIO
Prev Close
1025.85
Open Price
1064
Volume
17,109
Today Low / High
1041.55 / 1077.1
52 WK Low / High
373.65 / 1077.1
Range
1,023 - 1,131
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 1077.1, reflecting a change of 51.25 (4.99586%). The expected target range on the BSE is 1,023 - 1,131. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Titan Biotech Limited Graph
Titan Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Titan Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,077.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,077.10 | 1,087.87 | 979.08 - 1,196.66 |
| 1,098.64 | 878.91 - 1,318.37 | ||
| 1,109.41 | 776.59 - 1,442.24 | ||
| Bearish Scenario | 1,077.10 | 1,066.33 | 959.70 - 1,172.96 |
| 1,055.56 | 844.45 - 1,266.67 | ||
| 1,044.79 | 731.35 - 1,358.22 |
Overview of Titan Biotech Limited
ISIN
INE150C01011
Industry
Biotechnology
Vol.Avg
19,980
Market Cap
8,900,831,270
Last Dividend
2
Official Website
IPO Date
2000-11-30
DCF Diff
710.91
DCF
366
Financial Ratios Every Investor Needs
Stock Dividend of TITANBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-19 | September 19, 25 | 2 | 2 | 2025-09-19 | 2025-10-26 | |
| 2024-09-23 | September 23, 24 | 2 | 2 | 2024-09-23 | 2024-10-30 | |
| 2023-09-22 | September 22, 23 | 1.8 | 1.8 | 2023-09-22 | 2023-10-29 | |
| 2022-09-22 | September 22, 22 | 1.5 | 1.5 | 2022-09-23 | 2022-10-30 | |
| 2021-09-16 | September 16, 21 | 1.5 | 1.5 | 2021-09-17 | 2021-10-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 156.45 Cr | 72.63 Cr | 83.82 Cr | 0.5358 | 0.00 Cr | 26.95 Cr | 21.26 Cr | 21.53 Cr | 26.04 | 29.34 Cr | 0.1376 |
| 2024-03-31 | 164.07 Cr | 120.78 Cr | 43.30 Cr | 0.2639 | 0.13 Cr | 2.39 Cr | 31.59 Cr | 24.85 Cr | 30.07 | 35.80 Cr | 0.1515 |
| 2023-03-31 | 144.00 Cr | 85.64 Cr | 58.36 Cr | 0.4053 | 0.10 Cr | 1.84 Cr | 51.81 Cr | 24.84 Cr | 30.06 | 31.46 Cr | 0.1725 |
| 2022-03-31 | 123.55 Cr | 70.53 Cr | 53.02 Cr | 0.4291 | 0.00 Cr | 1.40 Cr | 29.24 Cr | 21.68 Cr | 26.24 | 32.03 Cr | 0.1755 |
| 2021-03-31 | 142.24 Cr | 75.28 Cr | 66.95 Cr | 0.4707 | 0.18 Cr | 1.51 Cr | 44.37 Cr | 30.34 Cr | 36.71 | 46.40 Cr | 0.2133 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 5.13 Cr | 174.71 Cr | 21.30 Cr | 153.4032 Cr | 2.80 Cr | -2.33 Cr | 50.72 Cr | 58.85 Cr | 0.00 Cr | 0.00 Cr | 34.79 Cr | 17.7364 Cr |
| 2024-03-31 | 2.84 Cr | 157.63 Cr | 23.57 Cr | 133.4512 Cr | 8.30 Cr | 5.46 Cr | 46.61 Cr | 54.47 Cr | 1.96 Cr | 0.00 Cr | 28.55 Cr | 19.1252 Cr |
| 2023-03-31 | 4.86 Cr | 134.52 Cr | 24.60 Cr | 109.9109 Cr | 8.51 Cr | 3.65 Cr | 36.17 Cr | 49.10 Cr | 2.09 Cr | 0.00 Cr | 15.67 Cr | 20.3505 Cr |
| 2022-03-31 | 6.81 Cr | 108.09 Cr | 21.85 Cr | 86.2441 Cr | 8.93 Cr | 2.12 Cr | 34.68 Cr | 38.51 Cr | 1.27 Cr | 0.00 Cr | 4.19 Cr | 16.9494 Cr |
| 2021-03-31 | 5.45 Cr | 100.72 Cr | 28.24 Cr | 68.7582 Cr | 14.79 Cr | 9.34 Cr | 32.54 Cr | 33.79 Cr | 0.00 Cr | 0.00 Cr | 7.83 Cr | 19.2796 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 20.1233 Cr | -9.8747 Cr | -7.9608 Cr | 10.6793 Cr | 2.2878 Cr | 5.1279 Cr | -9.3901 Cr | 21.5316 Cr | -5.0688 Cr | -1.6527 Cr | -5.1518 Cr |
| 2024-03-31 | 21.1463 Cr | -20.3037 Cr | -2.8662 Cr | 1.4567 Cr | -2.0236 Cr | 2.8401 Cr | -19.6896 Cr | 24.8530 Cr | 0.1724 Cr | -1.4875 Cr | -9.4015 Cr |
| 2023-03-31 | 21.1783 Cr | -20.7252 Cr | -2.4034 Cr | 8.4446 Cr | -1.9502 Cr | 4.8637 Cr | -13.1702 Cr | 28.1161 Cr | -0.5328 Cr | -1.2396 Cr | -1.4898 Cr |
| 2022-03-31 | 22.0407 Cr | -16.4366 Cr | -4.0988 Cr | 8.3604 Cr | 1.5054 Cr | 6.8139 Cr | -18.7850 Cr | 28.9690 Cr | -1.7369 Cr | -1.2396 Cr | -9.7567 Cr |
| 2021-03-31 | 19.0821 Cr | -4.8649 Cr | -10.5993 Cr | 14.2172 Cr | 3.6179 Cr | 5.4506 Cr | -4.8649 Cr | 42.7056 Cr | -9.7538 Cr | -0.8264 Cr | -4.5620 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 46.50 Cr | 23.95 Cr | 22.55 Cr | 0.4849 | 7.59 Cr | 6.86 Cr | 8.30 | 9.46 Cr | 0.1476 |
| 2025-03-31 | 35.17 Cr | 15.01 Cr | 20.16 Cr | 0.5731 | 3.73 Cr | 4.05 Cr | 4.89 | 5.95 Cr | 0.1151 |
| 2024-12-31 | 38.28 Cr | 18.34 Cr | 19.94 Cr | 0.5209 | 3.66 Cr | 4.39 Cr | 5.31 | 6.44 Cr | 0.1147 |
| 2024-09-30 | 39.89 Cr | 17.51 Cr | 22.38 Cr | 0.5610 | 6.66 Cr | 6.70 Cr | 8.10 | 8.08 Cr | 0.1678 |
| 2024-06-30 | 43.11 Cr | 29.09 Cr | 14.03 Cr | 0.3254 | 7.20 Cr | 6.40 Cr | 7.74 | 8.87 Cr | 0.1484 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 5.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -153.40 Cr |
| 2025-03-31 | 5.13 Cr | 0.43 Cr | 5.56 Cr | 18.82 Cr | 50.72 Cr | 79.04 Cr | 58.85 Cr | 174.71 Cr | 21.30 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 10.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -144.98 Cr |
| 2024-09-30 | 8.06 Cr | 1.97 Cr | 10.03 Cr | 24.04 Cr | 49.29 Cr | 91.40 Cr | 59.21 Cr | 173.10 Cr | 28.12 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 2.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -133.45 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 6.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 4.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 4.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 6.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 6.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹349.00 | ₹465,763,304,358.00 | ₹3,503,002.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹193.80 | ₹256,620,093,061.00 | ₹1,781,622.00 |
| Syngene International Limited | SYNGENE | ₹630.65 | ₹253,133,061,139.00 | ₹859,527.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,609.20 | ₹168,348,395,477.00 | ₹309,020.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹663.55 | ₹115,102,982,759.00 | ₹246,061.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹654.55 | ₹103,508,092,256.00 | ₹231,433.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹715.55 | ₹57,589,467,540.00 | ₹63,151.00 |
| Zota Health Care Limited | ZOTA | ₹1,484.00 | ₹45,013,660,020.00 | ₹24,128.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹286.50 | ₹44,918,356,718.00 | ₹325,836.00 |
| Panacea Biotec Limited | PANACEABIO | ₹431.15 | ₹26,408,259,138.00 | ₹140,902.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1959
Gender: male
Year Born:
Gender: male
Year Born: 1960
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1993
FAQs about Titan Biotech Limited
The CEO is Naresh Kumar Singla.
The current price is ₹1,077.10.
The range is ₹373.65-1077.1.
The market capitalization is ₹890.08 crores.
The dividend yield is 0.19%.
The P/E ratio is 40.49.
The company operates in the Healthcare sector.
Overview of Titan Biotech Limited (ISIN: INE150C01011) is a leading Biotechnology in India. With a market capitalization of ₹890.08 crores and an average daily volume of 19,980 shares, it operates in the Biotechnology. The company last declared a dividend of ₹2.